Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway

The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14ARF and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rb and/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.

[1]  J. McDougall,et al.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. , 2000, The American journal of pathology.

[2]  R. North,et al.  Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter , 1991, Nature.

[3]  M. Knowles,et al.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. , 2004, The Journal of molecular diagnostics : JMD.

[4]  G. Peters,et al.  Immortalisation and transformation revisited. , 2002, Current opinion in genetics & development.

[5]  G. Hannon,et al.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Bond,et al.  Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation. , 2004, Experimental cell research.

[7]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[8]  D. F. Thomas,et al.  Urothelial tissue culture for bladder reconstruction: an experimental study. , 1993, The Journal of urology.

[9]  Robert A. Weinberg,et al.  Telomerase contributes to tumorigenesis by a telomere length-independent mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[11]  W. Hahn,et al.  Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics , 2000, Molecular and Cellular Biology.

[12]  N. Carter,et al.  High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization , 2004, Oncogene.

[13]  M. Rahat,et al.  Telomerase activity in patients with transitional cell carcinoma , 1999, Cancer.

[14]  J. Munro,et al.  Telomerase alone extends the replicative life span of human skeletal muscle cells without compromising genomic stability. , 2003, Human gene therapy.

[15]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[16]  M. S. Burger,et al.  Replicative senescence in human uroepithelial cells. , 1999, Advances in experimental medicine and biology.

[17]  W. Hahn,et al.  A Two-Stage, p16INK4A- and p53-Dependent Keratinocyte Senescence Mechanism That Limits Replicative Potential Independent of Telomere Status , 2002, Molecular and Cellular Biology.

[18]  R. Weinberg,et al.  Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase , 1998, Oncogene.

[19]  C. Reznikoff,et al.  Dominant genetic alterations in immortalization: Role for 20q gain , 1999, Genes, chromosomes & cancer.

[20]  M. Newton,et al.  Overcoming cellular senescence in human cancer pathogenesis. , 1998, Genes & development.

[21]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[22]  C. Reznikoff,et al.  Urological Survey: Abstracts: Principles of Oncology, and Tumors of Bladder, Penis and UrethraTelomerase Activity: A Biomarker of Cell Proliferation, Not Malignant Transformation , 1998 .

[23]  L. Latonen,et al.  hTERT antagonizes p53-induced apoptosis independently of telomerase activity , 2005, Oncogene.

[24]  J. Bond,et al.  Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Elmore,et al.  Adriamycin-induced Senescence in Breast Tumor Cells Involves Functional p53 and Telomere Dysfunction* , 2002, The Journal of Biological Chemistry.

[26]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[27]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[28]  M. Knowles,et al.  What we could do now: molecular pathology of bladder cancer , 2001, Molecular pathology : MP.

[29]  E. Parkinson,et al.  Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-β: but p53 mutations are not necessarily required , 2003, Oncogene.

[30]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[31]  Elena Savelieva,et al.  20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells , 1997, Oncogene.

[32]  D. Wazer,et al.  Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Smith,et al.  Control of Replicative Life Span in Human Cells: Barriers to Clonal Expansion Intermediate Between M1 Senescence and M2 Crisis , 1999, Molecular and Cellular Biology.

[34]  R. Alani,et al.  Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Knowles,et al.  Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.

[36]  James M. Roberts,et al.  Telomerase modulates expression of growth-controlling genes and enhances cell proliferation , 2003, Nature Cell Biology.

[37]  Andrea Bodnar,et al.  Human Endothelial Cell Life Extension by Telomerase Expression* , 1999, The Journal of Biological Chemistry.

[38]  J. Shay,et al.  Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. , 2001, Genes & development.